NCT05482282: Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) |
|
|
| Not yet recruiting | 3 | 220 | RoW | Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma), Pentabio | PT Bio Farma, Hasan Sadikin General Hospital | Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction, Haemophilus Influenzae Type B Vaccine Adverse Reaction, Hepatitis B Vaccine Adverse Reaction | 04/25 | 07/25 | | |
NCT06608199: A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine |
|
|
| Not yet recruiting | 3 | 500 | RoW | pneumococcal disease prevention | Beijing Minhai Biotechnology Co., Ltd | Pneumococcal Vaccines, Pneumococcal Infections | 06/25 | 10/26 | | |
NCT05387317: Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) |
|
|
| Withdrawn | 3 | 800 | RoW | Pfizer-BioNTech Standard dose, BNT162b2, Comirnaty, AstraZeneca Standard dose, ChAdOx1-S, Vaxzevria, Pfizer-BioNTech Fractional dose, AstraZeneca Fractional dose, Moderna Standard dose, mRNA-1273, Spikevax®, Moderna Fractional dose | Murdoch Childrens Research Institute, Universitas Padjadjaran, Health Development Policy Agency, Ministry of Health Republic of Indonesia, Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity, Indonesia University | COVID-19 | 01/25 | 10/25 | | |
NCT05727215: Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age |
|
|
| Active, not recruiting | 2 | 150 | RoW | SARS-CoV-2 subunit protein recombinant vaccine | PT Bio Farma, Universitas Padjadjaran | COVID-19 | 06/23 | 02/24 | | |
